Evidence map›Paper›PMID 21960715›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2011

The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation.

Elvin H Geng, James S Kahn, Olivia C Chang, C Bradley Hare, Katerina A Christopoulos, Diane Jones, Maya L Petersen, Steven G Deeks, Diane V Havlir, Monica Gandhi

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Putting the Dissemination and Implementation in Infectious Diseases.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  2. Closing the gap: A novel metric of change in performance.East African journal of applied health monitoring and evaluation · 2019
    Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elvin H GengDivision of HIV/AIDS, San Francisco General Hospital, and Department of Medicine, 995 Potrero Avenue, San Francisco, CA 94110, USA. genge@php.ucsf.edu
James S Kahn
Olivia C Chang
C Bradley Hare
Katerina A Christopoulos
Diane Jones
Maya L Petersen
Steven G Deeks
Diane V Havlir
Monica Gandhi

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
Therapeutic Strategies for HIV DiseaseK24AI051982 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2002 to 2012
$1.3M
Randomized controlled trial embedded in an electronic health recordR18HS017784 · AHRQ · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAHN, JAMES S · 2008 to 2010
$1.2M
Adherence Improvement and Measurement- AIM- System. Challenge Topic 10-MH-101RC1MH088341 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAHN, JAMES S · 2009 to 2010
$998k
Optimizing Rapid and Full Engagement in Care for Persons with Newly Diagnosed HIVK23MH092220 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHRISTOPOULOS, KATERINA A · 2010 to 2013
$635k
Early Mortality in HIV Infected Patients Starting Antiretroviral Therapy in AfricK23AI084544 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GENG, ELVIN H. · 2009 to 2013
$621k
Mentoring HIV and Translational Scientists and Developing an EMR Based ResearchK24RR024369 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAHN, JAMES S · 2007 to 2011
$553k
AHRQ HHS R18 HS017784AHRQ HHS R18 HS17784NCRR NIH HHS K24 RR024369NCRR NIH HHS RR 024369NIAID NIH HHS K23 AI084544NIAID NIH HHS K24 AI051982NIAID NIH HHS P30 AI027763NIAID NIH HHS UM1 AI069496NIMH NIH HHS K23 MH092220NIMH NIH HHS MH 088341NIMH NIH HHS RC1 MH088341PHS HHS R24 A067039
6 · The paper itself

Abstract

backgroundDiffusion, dissemination, and implementation of scientific evidence into routine clinical practice is not well understood. The Adult AIDS Clinical Trials Group (ACTG) Protocol 5164 showed that early antiretroviral therapy (ART; ie, within 14 days) after diagnosis of an opportunistic infection improved clinical outcomes, compared with later initiation. Subsequently, the San Francisco General Hospital (SFGH) HIV/AIDS Service performed the SFGH 5164 Initiative to disseminate and implement the findings of ACTG 5164.

methodsWe evaluated patients who received a diagnosis of Pneumocystis jirovecii pneumonia (PCP) from 1 January 2001 through 30 March 2011. Survival analyses were used to assess changes in the time to initiation of ART after PCP, and logistic regression was used to evaluate changes in the odds of early ART (ie, within 14 days) because of ACTG 5164 and SFGH 5164 Initiative.

resultsAmong 162 patients, the adjusted hazard of ART initiation increased by 3.05 (95% confidence interval [CI], 1.86-5.02) after ACTG 5164 and by 4.89 (95% CI, 2.76-8.67) after the SFGH Initiative, compared with before ACTG 5164. When compared with before ACTG 5164, the proportion of patients who received ART within the 14 days after PCP diagnosis increased from 7.4% to 50.0% (P < .001) after ACTG 5164 and from 50.0% to 83.0% (P = .02) after the SFGH 5164 Initiative.

conclusionsDiffusion of findings from of a randomized trial changed practice at an academic medical center, but dissemination and implementation efforts were required to establish early ART at acceptable levels. Early ART initiation can be achieved in real-world patient populations.

Indexed as

Antiretroviral Therapy, Highly ActivePneumocystis cariniiAdultAIDS-Related Opportunistic InfectionsDiffusion of InnovationFemaleHIV InfectionsHumansMaleMiddle AgedPneumonia, PneumocystisRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeViral Load

Identifiers

PMID21960715
PMCPMC3193829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.